{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T06:09:29Z","timestamp":1772431769456,"version":"3.50.1"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the long-term survival and safety outcomes of CD20-targeted chemoimmunotherapy regimens in patients with Waldenstrom macroglobulinemia (WM) in a real-world single-center cohort from China.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a retrospective analysis of 128 patients with WM who received CD20-based regimens at a single center from 2014 to 2024. Baseline characteristics, treatment efficacy, survival outcomes (OS and PFS) and safety profiles were compared among the four treatment groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Significant differences were found in age, disease burden, and bone marrow infiltration. Patients in the R-CHOP group had higher IgM levels and bone marrow infiltration rates. The FCR group achieved the longest OS (75.86 \u00b1 22.05 months,\n                      <jats:italic>P<\/jats:italic>\n                      &amp;lt; 0.01). The RTX group showed the poorest outcomes, with a mortality rate of 75% within 12 months after relapse. ORR and consolidation therapy rates were similar across groups. The FCR group had the highest rate of grade \u22653 adverse events (60%), mainly leukopenia and thrombocytopenia. The R-CHOP group had a higher infection risk, while RTX was the safest.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this 10-year single-center real-world cohort from China, CD20-targeted chemoimmunotherapy achieved durable disease control with acceptable long-term safety in patients with WM. Differences in efficacy and toxicity profiles among FCR, BR, R-CHOP, and rituximab monotherapy support an individualized treatment approach that takes into account patient age, comorbidities, and tolerance. Because standardized quality-of-life instruments were not used in this retrospective study, our findings should be interpreted as reflecting survival and treatment-related toxicity rather than validated health-related quality of life.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1733209","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T05:21:01Z","timestamp":1772428861000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["A real-world 10-year follow-up analysis of survival and safety of CD20-targeted therapy in patients with Waldenstrom macroglobulinemia"],"prefix":"10.3389","volume":"16","author":[{"given":"Hengming","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Pathology, WeiFang People's Hospital","place":["Weifang, Shandong, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xufei","family":"Huang","sequence":"additional","affiliation":[{"name":"Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Hematology Department, Fujian Medical University Union Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yirong","family":"Zhu","sequence":"additional","affiliation":[{"name":"Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Hematology Department, Fujian Medical University Union Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihong","family":"Zheng","sequence":"additional","affiliation":[{"name":"Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Hematology Department, Fujian Medical University Union Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong","family":"Zhan","sequence":"additional","affiliation":[{"name":"Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Hematology Department, Fujian Medical University Union Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaoyuan","family":"Wang","sequence":"additional","affiliation":[{"name":"Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Hematology Department, Fujian Medical University Union Hospital","place":["Fuzhou, Fujian, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2024.102715","article-title":"How to manage waldenstrom\u2019s macroglobulinemia in 2024","volume":"125","author":"Grunenberg","year":"2024","journal-title":"Cancer Treat Rev"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26796","article-title":"Waldenstrom macroglobulinemia: 2023 update on diagnosis, risk stratification, and management","volume":"98","author":"Gertz","year":"2023","journal-title":"Am J Hematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.5763","article-title":"Diagnosis and management of waldenstrom macroglobulinemia: mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines 2016","volume":"3","author":"Kapoor","year":"2017","journal-title":"JAMA Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.lrr.2022.100324","article-title":"Monoclonal antibody-based therapies for Waldenstrom\u2019s macroglobulinemia","volume":"17","author":"Fotiou","year":"2022","journal-title":"Leuk Res Rep"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2022.02.005","article-title":"SOHO State of the Art Updates and Next Questions: Targeted therapies and emerging novel treatment approaches for Waldenstrom Macroglobulinemia","volume":"22","author":"Sermer","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B6","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s40265-024-02011-w","article-title":"Drugs targeting CD20 in multiple sclerosis: pharmacology, efficacy, safety, and tolerability","volume":"84","author":"Carlson","year":"2024","journal-title":"Drugs"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.48095\/ccko2023177","article-title":"Waldenstrom\u2019s macroglobulinemia - clinical symptoms and review of therapy yesterday, today and tomorrow","volume":"36","author":"Adam","year":"2023","journal-title":"Klin Onkol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12050676","article-title":"The use of bruton tyrosine kinase inhibitors in waldenstrom\u2019s macroglobulinemia","volume":"12","author":"Khan","year":"2022","journal-title":"J Pers Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.11406\/rinketsu.64.54","article-title":"Lymphoplasmacytic lymphoma accompanied by severe myelofibrosis","volume":"64","author":"Takarada","year":"2023","journal-title":"Rinsho Ketsueki"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.5603\/PJNNS.a2023.0022","article-title":"Targeting CD20 in multiple sclerosis - review of current treatment strategies","volume":"57","author":"Chmielewska","year":"2023","journal-title":"Neurol Neurochir Pol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2022.100527","article-title":"Current approach to waldenstrom macroglobulinemia","volume":"31","author":"Ravi","year":"2022","journal-title":"Cancer Treat Res Commun"},{"key":"B12","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1002\/hon.3172","article-title":"Unmet clinical needs in the use of zanubrutinib in Malignant lymphomas (Waldenstrom macroglobulinemia, marginal zone lymphoma and mantle cell lymphoma): A consensus-based position paper from an ad hoc expert panel","volume":"41","author":"Zinzani","year":"2023","journal-title":"Hematol Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-08-174961","article-title":"International prognostic scoring system for Waldenstrom macroglobulinemia","volume":"113","author":"Morel","year":"2009","journal-title":"Blood"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3760\/cma.j.issn.0253-2727.2022.08.002","article-title":"Chinese guideline for diagnosis and treatment of lymphoplasmacytic lymphoma\/Walderstrom macroglobulinemia (2022)","volume":"43","year":"2022","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.02.010","article-title":"Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0","volume":"67","author":"Chen","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1053\/j.seminhematol.2023.03.008","article-title":"The epidemiology of Waldenstrom macroglobulinemia","volume":"60","author":"McMaster","year":"2023","journal-title":"Semin Hematol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e240001","DOI":"10.6004\/jnccn.2024.0001","article-title":"Waldenstrom macroglobulinemia\/lymphoplasmacytic lymphoma, version 2.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Kumar","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e14514","DOI":"10.1111\/ctr.14514","article-title":"A modified conditioning regimen based on low-dose cyclophosphamide and fludarabine for haploidentical hematopoietic stem cell transplant in severe aplastic anemia patients at risk of severe cardiotoxicity","volume":"36","author":"Lin","year":"2022","journal-title":"Clin Transplant"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.03.029","article-title":"Clinical features of acute kidney injury in the early post-transplantation period following reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation","volume":"29","author":"Vergara-Cadavid","year":"2023","journal-title":"Transplant Cell Ther"},{"key":"B20","doi-asserted-by":"publisher","first-page":"48","DOI":"10.3892\/ol.2022.13634","article-title":"BTK inhibitor combined with anti-PD-1 monoclonal antibody for the treatment of CD20-negative primary central nervous system lymphoma: A case report","volume":"25","author":"Feng","year":"2023","journal-title":"Oncol Lett"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17050907","article-title":"Molecular mechanisms in the transformation from indolent to aggressive B cell Malignancies","volume":"17","author":"Maher","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"iv270","DOI":"10.1093\/annonc\/mdy322","article-title":"Waldenstr\u00f6m\u2019s macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Kastritis","year":"2018","journal-title":"Ann Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006844","article-title":"A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenstr\u00f6m macroglobulinemia: the ASPEN study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1200\/jco.22.02830","article-title":"Zanubrutinib versus ibrutinib in symptomatic waldenstr\u00f6m macroglobulinemia: final analysis from the randomized phase III ASPEN study","volume":"41","author":"Dimopoulos","year":"2023","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 trial of ibrutinib plus rituximab in Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1733209\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T05:21:02Z","timestamp":1772428862000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1733209\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":25,"alternative-id":["10.3389\/fonc.2026.1733209"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1733209","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]},"article-number":"1733209"}}